VisualMED sets sights on U.S. oncology EMR market
Healthcare information systems developer VisualMED Clinical Solutions of Montreal said that it has begun a comprehensive sales effort for its VisualOncology application by targeting some of the United States' major cancer centers. The product, which can be integrated as part of an electronic medical record (EMR), is used by clinicians to prescribe protocol chemotherapy and is used by oncology staff to the review the day-to-day progress of patients in the context of the currently active protocol.
The company estimates that about 800 U.S. sites represent potential client installations in the intermediate term and believes it can win a 5 percent market share over the next 30 months in this niche.
VisualMED CEO Gerad Dab said that a 5 percent market share represents about 40 intermediate to large-size oncology practices. The firm expects average sales prices to range from $250,000 to $1 million (U.S.) with a 20 percent annual maintenance fee.
Gerard said that he expects these sites to each generate between $25,000 and $200,000 (U.S.) per year in recurring systems maintenance revenue.
The company estimates that about 800 U.S. sites represent potential client installations in the intermediate term and believes it can win a 5 percent market share over the next 30 months in this niche.
VisualMED CEO Gerad Dab said that a 5 percent market share represents about 40 intermediate to large-size oncology practices. The firm expects average sales prices to range from $250,000 to $1 million (U.S.) with a 20 percent annual maintenance fee.
Gerard said that he expects these sites to each generate between $25,000 and $200,000 (U.S.) per year in recurring systems maintenance revenue.